Form 8-K - Current report:
SEC Accession No. 0001193125-24-163507
Filing Date
2024-06-18
Accepted
2024-06-18 17:12:01
Documents
15
Period of Report
2024-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d853800d8k.htm   iXBRL 8-K 44395
2 EX-3.1 d853800dex31.htm EX-3.1 6008
3 EX-10.1 d853800dex101.htm EX-10.1 67307
  Complete submission text file 0001193125-24-163507.txt   269606

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA elvn-20240618.xsd EX-101.SCH 2887
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20240618_lab.xml EX-101.LAB 18724
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20240618_pre.xml EX-101.PRE 11729
18 EXTRACTED XBRL INSTANCE DOCUMENT d853800d8k_htm.xml XML 3836
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 241052944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)